Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 21Breast 12Other hematologic neoplasm 10Sarcoma 5Genitourinary 4CNS 4Thoracic 3Gynecologic 3Plasma cell 2Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Amyloidosis 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
pegfilgrastim × Plasma cell × 1 year × Clear all
NCT07188090 2025-11-28

HSCT

Thomas Jefferson University

Phase 2 Recruiting
100 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02909036 2025-10-10

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
46 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡